BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 29304773)

  • 21. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
    Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
    Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
    Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
    Yang PS; Chen CM; Liu MC; Jian JM; Horng CF; Liu MJ; Yu BL; Lee MY; Chi CW
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):516-22. PubMed ID: 19577858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
    Woodward WA; Strom EA; Tucker SL; Katz A; McNeese MD; Perkins GH; Buzdar AU; Hortobagyi GN; Hunt KK; Sahin A; Meric F; Sneige N; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):336-44. PubMed ID: 12957243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of de-escalating systemic therapy guided by 21-gene assay on locoregional recurrence after partial-breast irradiation.
    Sato K; Takeda N; Fuchikami H; Natsume N; Kato M; Okawa T
    Brachytherapy; 2023; 22(3):381-388. PubMed ID: 36894345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Locoregional recurrence risk factors and the impact of postmastectomy radiotherapy on patients with tumors 5 cm or larger.
    Nagao T; Kinoshita T; Tamura N; Hojo T; Morota M; Kagami Y
    Breast Cancer; 2014 May; 21(3):292-301. PubMed ID: 22890603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
    Wolf I; Ben-Baruch N; Shapira-Frommer R; Rizel S; Goldberg H; Yaal-Hahoshen N; Klein B; Geffen DB; Kaufman B
    Cancer; 2008 Feb; 112(4):731-6. PubMed ID: 18076012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
    Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
    Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
    Fodor J
    Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
    Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
    Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
    Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
    Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
    J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
    Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
    Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy.
    Truong PT; Lee J; Kader HA; Speers CH; Olivotto IA
    Eur J Cancer; 2005 Jun; 41(9):1267-77. PubMed ID: 15939262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.